GlobeNewswire: Esperion Therapeutics, Inc. Contains the last 10 of 283 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T11:44:47ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/26/2852288/0/en/Esperion-to-Participate-in-23rd-Annual-Needham-Virtual-Healthcare-Conference.html?f=22&fvtc=4&fvtv=28003Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference2024-03-26T12:00:00Z<![CDATA[ANN ARBOR, Mich., March 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the 23rd Annual Needham Virtual Healthcare Conference. Sheldon Koenig, President and CEO, will participate in a fireside chat on Tuesday, April 9, 2024, at 12:45 PM ET. The Esperion management team will also host investor meetings that same day.]]>https://www.globenewswire.com/news-release/2024/03/25/2851972/0/en/Esperion-Announces-Data-from-CLEAR-Outcomes-Sub-Groups-as-Poster-Presentations-Moderated-Session-Industry-Expert-Theatre-to-be-Presented-at-ACC-24.html?f=22&fvtc=4&fvtv=28003Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.242024-03-25T20:00:00Z<![CDATA[ANN ARBOR, Mich., March 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the acceptance of three CLEAR (Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen) Outcomes subgroup analyses as poster presentations at the 2024 American College of Cardiology’s Annual Scientific Session (ACC.24) in Atlanta, Georgia. Additionally, the Company will participate in a moderated session in partnership with UT Southwestern Medical Center, host an industry expert theatre, and have a commercial and medical information booth during ACC.24.]]>https://www.globenewswire.com/news-release/2024/03/22/2851118/0/en/U-S-FDA-Approves-Broad-New-Labels-for-NEXLETOL-and-NEXLIZET-to-Prevent-Heart-Attacks-and-Cardiovascular-Procedures-in-Both-Primary-and-Secondary-Prevention-Patients-Regardless-of-S.html?f=22&fvtc=4&fvtv=28003U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use2024-03-22T19:10:20Z<![CDATA[– New Labels Expand Treatable Population to ~70 Million Patients in U.S. –]]>https://www.globenewswire.com/news-release/2024/03/22/2851118/0/en/U-S-FDA-Approves-Broad-New-Labels-for-NEXLETOL-and-NEXLIZET-to-Prevent-Heart-Attacks-and-Cardiovascular-Procedures-in-Both-Primary-and-Secondary-Prevention-Patients-Regardless-of-S.htmlNEXLETOL® (bempedoic acid) TabletProduction Linehttps://www.globenewswire.com/news-release/2024/03/22/2851030/0/en/CHMP-Issues-Positive-Opinions-For-Both-Bempedoic-Acid-And-The-Bempedoic-Acid-Ezetimibe-Fixed-Dose-Combination-Tablet-As-Treatments-For-Hypercholesterolemia-And-Significantly-Reduci.html?f=22&fvtc=4&fvtv=28003CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events2024-03-22T15:04:39Z<![CDATA[– Positive CHMP Opinions Are Based On The Analyses Of The Phase 3 Of The CLEAR (Cholesterol Lowering via Bempedoic Acid, an ATP Citrate Lyase (ACL)-Inhibiting Regimen) Outcomes Trial1 –]]>https://www.globenewswire.com/news-release/2024/02/27/2835780/0/en/Esperion-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html?f=22&fvtc=4&fvtv=28003Esperion Reports Fourth Quarter and Full Year 2023 Financial Results2024-02-27T11:00:00Z<![CDATA[– FY23 U.S. Net Product Revenue Grew 40% Y/Y to $78.3 Million; FY23 Total Revenue Grew 54% Y/Y to $116.3 Million –]]>https://www.globenewswire.com/news-release/2024/02/16/2830947/0/en/Esperion-Announces-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=28003Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)2024-02-16T21:30:00Z<![CDATA[ANN ARBOR, Mich., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on February 13, 2024, the Company granted 66 new employees 204,900 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan.]]>https://www.globenewswire.com/news-release/2024/02/13/2828156/0/en/Esperion-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-February-27.html?f=22&fvtc=4&fvtv=28003Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 272024-02-13T13:00:00Z<![CDATA[ANN ARBOR, Mich., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report fourth quarter and full year 2023 financial results before the market opens on Tuesday, February 27, 2024.]]>https://www.globenewswire.com/news-release/2024/02/01/2822389/0/en/RFK-Esperion-Therapeutics-Announce-2024-Promotional-Schedule.html?f=22&fvtc=4&fvtv=28003RFK, Esperion Therapeutics Announce 2024 Promotional Schedule2024-02-01T19:00:00Z<![CDATA[NEXLETOL and NEXLIZET to Ride Along RFK Mustangs in Four Races in 2024 NEXLETOL and NEXLIZET to Ride Along RFK Mustangs in Four Races in 2024]]>https://www.globenewswire.com/news-release/2024/01/23/2814497/0/en/Esperion-Announces-Closing-of-Public-Offering-of-Common-Stock-and-Exercise-in-Full-of-Underwriters-Option-to-Purchase-Additional-Shares.html?f=22&fvtc=4&fvtv=28003Esperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares2024-01-23T21:00:00Z<![CDATA[ANN ARBOR, Mich., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (“Esperion”, “we”, “us” or “our”) (Nasdaq: ESPR) announced today the closing of its previously announced underwritten public offering of 65,205,000 shares of its common stock, including 8,505,000 shares of its common stock pursuant to the underwriters’ exercise in full of their option to purchase additional shares of common stock, at the public offering price of $1.50 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Esperion, are approximately $97.8 million.]]>https://www.globenewswire.com/news-release/2024/01/19/2812076/0/en/Esperion-Announces-Pricing-of-85-1-Million-Public-Offering-of-Common-Stock.html?f=22&fvtc=4&fvtv=28003Esperion Announces Pricing of $85.1 Million Public Offering of Common Stock2024-01-19T02:15:58Z<![CDATA[ANN ARBOR, Mich., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (“Esperion”, “we”, “us” or “our”) (Nasdaq: ESPR) announced today the pricing of its previously announced underwritten public offering of 56,700,000 shares of its common stock at a public offering price of $1.50 per share, before underwriting discounts and commissions. All of the shares of common stock are being offered by Esperion. In addition, Esperion granted the underwriters a 30-day option to purchase up to an additional 8,505,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Esperion, are expected to be approximately $85.1 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on January 23, 2024, subject to customary closing conditions.]]>